NCNA VS MTCR Stock Comparison

Performance

NCNA
10/100

NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.

MTCR
100/100

MTCR returned -2.83% in the last 12 months. Based on the other stocks in it's sector with an average return of -24.04%, it's performance is above average giving it a grade of 100 of 100.

Analyst Price Targets

NCNA
94/100

4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.

MTCR

"Analyst Price Targets" not found for MTCR

Sentiment

NCNA
65/100

NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.

MTCR
10/100

MTCR does not have any recent conclusive social sentiment.

Technicals

NCNA
11/100

NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

MTCR
64/100

MTCR receieves a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

NCNA
10/100

NCNA has missed earnings 7 times in the last 20 quarters.

MTCR
10/100

MTCR has missed earnings 6 times in the last 20 quarters.

Profit

NCNA
10/100

Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

MTCR
10/100

Out of the last 7 quarters, MTCR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NCNA
54/100

NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

MTCR
55/100

MTCR has had a higher than average amount of volatility over the last 12 months giving it a grade of 55 of 100.

Forecast

NCNA

"Forecast" not found for NCNA

MTCR
88/100

4 analysts offer 12-month price forecasts for MTCR. Together, they have an average target of 0, the most optimistic forecast put MTCR at 0 within 12-months and the most pessimistic has MTCR at 0.

Dividend

NCNA

"Dividend" not found for NCNA

MTCR
10/100

MTCR has not paid a dividend in the last 5 years.

All score calculations are broken down here to help you make more informed investing decisions

NuCana plc American Depositary Share Summary

Nasdaq / NCNA

Healthcare

Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Metacrine, Inc. Common Stock Summary

Nasdaq / MTCR

Healthcare

Biotechnology

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Power up your portfolio